ATE121787T1 - Neuer monoklonaler antikörper gegen menschliches karzinom. - Google Patents
Neuer monoklonaler antikörper gegen menschliches karzinom.Info
- Publication number
- ATE121787T1 ATE121787T1 AT89403631T AT89403631T ATE121787T1 AT E121787 T1 ATE121787 T1 AT E121787T1 AT 89403631 T AT89403631 T AT 89403631T AT 89403631 T AT89403631 T AT 89403631T AT E121787 T1 ATE121787 T1 AT E121787T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- monoclonal antibody
- carcinoma cells
- antibody against
- against human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28963588A | 1988-12-22 | 1988-12-22 | |
US07/443,696 US5242824A (en) | 1988-12-22 | 1989-11-29 | Monoclonal antibody to human carcinomas |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE121787T1 true ATE121787T1 (de) | 1995-05-15 |
Family
ID=26965758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT89403631T ATE121787T1 (de) | 1988-12-22 | 1989-12-22 | Neuer monoklonaler antikörper gegen menschliches karzinom. |
Country Status (7)
Country | Link |
---|---|
US (1) | US5242824A (de) |
EP (1) | EP0375562B1 (de) |
JP (1) | JPH04502702A (de) |
AT (1) | ATE121787T1 (de) |
CA (1) | CA2006353A1 (de) |
DE (1) | DE68922385T2 (de) |
ES (1) | ES2072914T3 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2090105A1 (en) * | 1990-08-29 | 1992-03-01 | Jean-Paul Soulillou | Protein polyligands joined to a stable protein core |
US5608039A (en) * | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
ATE218889T1 (de) * | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
ATE179604T1 (de) * | 1991-01-08 | 1999-05-15 | Bone Care Int Inc | Verfahren zur herstellung und verwendung von 1alpha,24-dihydroxy vitamin-d2 |
US6166000A (en) * | 1991-01-08 | 2000-12-26 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-Dihydroxy vitamin . D.sub2 |
US20040009958A1 (en) * | 1991-01-08 | 2004-01-15 | Bone Care International, Inc. | Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2 |
DE4237649C2 (de) * | 1992-11-07 | 2003-02-20 | Klaus Decken | Verfahren zur immunologischen Untersuchung von Zellen aus Körperflüssigkeiten |
WO1995012414A1 (en) * | 1993-11-05 | 1995-05-11 | Repligen Corporation | Novel modified pf4 compositions and methods of use |
US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5977316A (en) * | 1995-01-17 | 1999-11-02 | The Board Of Trustees Of The University Of Kentucky | Monoclonal antibody 1A7 and related polypeptides |
US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US5612030A (en) * | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
US6949244B1 (en) * | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
US5744585A (en) * | 1995-03-16 | 1998-04-28 | Medenica; Rajko D. | Human monoclonal antibody against lung carcinoma |
US5773292A (en) * | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
FR2746398B1 (fr) * | 1996-03-21 | 1998-04-30 | Bio Merieux | Anticorps specifique de staphylococcus aureaus, et utilisations |
US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
US6400678B1 (en) * | 1998-03-06 | 2002-06-04 | Hitachi, Ltd. | Disc cartridge |
US6794128B2 (en) * | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
AU778611B2 (en) | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
EP2289549A3 (de) * | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunokonjugate für Krebsbehandlung |
ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
ES2393733T3 (es) | 2001-03-07 | 2012-12-27 | Merck Patent Gmbh | Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
RU2306320C9 (ru) | 2001-05-03 | 2008-01-27 | Мерк Патент Гмбх | Рекомбинантное опухолеспецифичное антитело (варианты) и его применение |
CN100390282C (zh) | 2001-12-04 | 2008-05-28 | 默克专利有限公司 | 具有调节的选择性的il-2融合蛋白 |
GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
US7169904B2 (en) | 2002-12-17 | 2007-01-30 | Emd Lexigen Research Center Corp. | Immunocytokine sequences and uses thereof |
CA2518119A1 (en) * | 2003-03-05 | 2004-09-16 | Innexus Biotechnology Inc. | Trans-membrane-antibody induced inhibition of apoptosis |
EP1660538A1 (de) * | 2003-08-14 | 2006-05-31 | Wyeth | Antiidiotypische anti-lewis-y-antikörper und deren verwendungen |
RU2369616C2 (ru) | 2003-12-30 | 2009-10-10 | Мерк Патент Гмбх | Слитые белки il-7 |
EP1702069A2 (de) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Auf onkofötales fibronectin gerichtetes interleukin-12 |
US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
BRPI1016204A2 (pt) | 2009-04-22 | 2016-04-19 | Merck Patent Gmbh | proteínas de fusão de anticorpos com sítios de ligação fcrn modificados |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
JP5795765B2 (ja) | 2009-09-11 | 2015-10-14 | アメリカ合衆国 | 低減した免疫原性を有する改良型シュードモナス(Pseudomonas)外毒素A |
WO2011100455A1 (en) | 2010-02-12 | 2011-08-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibition of antibody responses to foreign proteins |
AU2012268013B2 (en) | 2011-06-09 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes |
US9206240B2 (en) | 2011-09-16 | 2015-12-08 | The United States of America, as represented by the Secretary, Department of Helath and Human Services | Pseudomonas exotoxin A with less immunogenic B cell epitopes |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
CA2926215A1 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
WO2017044530A1 (en) | 2015-09-08 | 2017-03-16 | Waters Technologies Corporation | Multidimensional chromatoggraphy method for analysis of antibody-drug conjugates |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
WO2019055955A1 (en) | 2017-09-18 | 2019-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
WO2021097289A1 (en) | 2019-11-15 | 2021-05-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pegylated recombinant immunotoxins |
US20230272116A1 (en) | 2020-07-10 | 2023-08-31 | Hoffmann-La Roche Inc. | Antibodies which bind to cancer cells and target radionuclides to said cells |
AU2022207615A1 (en) | 2021-01-12 | 2023-07-13 | F. Hoffmann-La Roche Ag | Split antibodies which bind to cancer cells and target radionuclides to said cells |
MX2023008083A (es) | 2021-01-13 | 2023-07-13 | Hoffmann La Roche | Tratamiento conjunto. |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4713352A (en) * | 1981-08-31 | 1987-12-15 | Sloan-Kettering Institute For Cancer Reseach | Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma |
US4612282A (en) * | 1981-12-15 | 1986-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibodies reactive with human breast cancer |
US4507391A (en) * | 1982-04-02 | 1985-03-26 | Sloan-Kettering Institute For Cancer Research | Method for detecting the presence of GD3 ganglioside |
US4618577A (en) * | 1983-02-09 | 1986-10-21 | The Regents Of The University Of California | Human-human hybridoma, CLNH5 |
US4713351A (en) * | 1983-01-28 | 1987-12-15 | The University Of Rochester | Monoclonal antibody directed to an antigen derived from human ovarian tumors and a radioimmunoassay using the antibody |
JPS59140900A (ja) * | 1983-01-28 | 1984-08-13 | Toyo Jozo Co Ltd | 新規な酵素的高感度測定法 |
US4613576A (en) * | 1983-03-09 | 1986-09-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cancer cells |
US4693966A (en) * | 1983-03-11 | 1987-09-15 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies from lymphocytes of patients with malignant melanoma |
US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
DK144485A (da) * | 1984-03-30 | 1985-10-01 | Syntex Inc | Monoklonale antistoffer |
US4886745A (en) * | 1984-03-30 | 1989-12-12 | Syntex Inc. | Monoclonal antibody specific for human basal cell surface antigen |
US4782015A (en) * | 1984-03-30 | 1988-11-01 | Syntex (U.S.A.) Inc. | Method for determining the presence of malignant cells |
US4683200A (en) * | 1984-05-17 | 1987-07-28 | Setsuo Hirohashi | Monoclonal antibody to human cancer antigen and method for producing same |
SE468231B (sv) * | 1984-05-18 | 1992-11-23 | Kabi Pharmacia Ab | Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos |
EP0173648A3 (de) * | 1984-08-30 | 1988-04-27 | Ciba-Geigy Ag | Monoklonale Antikörper gegen Glykokonjugate, Verfahren zu ihrer Herstellung und Verwendungen |
ZA858371B (en) * | 1984-11-02 | 1987-03-25 | Oncogen | Monoclonal antibodies for human non-small cell lung carcinomas |
US4708930A (en) * | 1984-11-09 | 1987-11-24 | Coulter Corporation | Monoclonal antibody to a human carcinoma tumor associated antigen |
CA1296660C (en) * | 1985-01-29 | 1992-03-03 | Walter P. Carney | Monoclonal antibody against a ras oncogene p21 related dodecapeptide |
US4863854A (en) * | 1985-08-12 | 1989-09-05 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to mucin-like human differentiation antigens |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
JPS6283898A (ja) * | 1985-10-09 | 1987-04-17 | Kyowa Hakko Kogyo Co Ltd | 抗ヒト肺腺癌特異的単クロ−ン性抗体 |
US4816402A (en) * | 1986-01-07 | 1989-03-28 | Northwestern University | Murine hybridoma and diagnostic antibody produced thereby |
JPS63157995A (ja) * | 1986-12-18 | 1988-06-30 | Kyowa Hakko Kogyo Co Ltd | 抗ヒト大腸癌単クロ−ン性抗体acc−574 |
-
1989
- 1989-11-29 US US07/443,696 patent/US5242824A/en not_active Expired - Fee Related
- 1989-12-21 CA CA002006353A patent/CA2006353A1/en not_active Abandoned
- 1989-12-22 EP EP89403631A patent/EP0375562B1/de not_active Expired - Lifetime
- 1989-12-22 AT AT89403631T patent/ATE121787T1/de active
- 1989-12-22 JP JP90501917A patent/JPH04502702A/ja active Pending
- 1989-12-22 DE DE68922385T patent/DE68922385T2/de not_active Expired - Fee Related
- 1989-12-22 ES ES89403631T patent/ES2072914T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH04502702A (ja) | 1992-05-21 |
EP0375562A3 (en) | 1990-09-12 |
DE68922385T2 (de) | 1995-10-12 |
DE68922385D1 (de) | 1995-06-01 |
CA2006353A1 (en) | 1990-06-22 |
US5242824A (en) | 1993-09-07 |
EP0375562A2 (de) | 1990-06-27 |
ES2072914T3 (es) | 1995-08-01 |
EP0375562B1 (de) | 1995-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68922385T2 (de) | Neuer monoklonaler Antikörper gegen menschliches Karzinom. | |
FR2584388B1 (fr) | Composition a base d'oxyde cerique, sa preparation et ses utilisations | |
NO915137L (no) | Hittil ukjente antistoffer som er reaktive med humankarsinomer | |
CA2249320A1 (en) | Glycosylated humanized b-cell specific antibodies | |
AU563356B2 (en) | Conjugate of enzyme and antibody | |
CA2072249A1 (en) | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane | |
ES2123677T3 (es) | Ligadores de maleinimida trifuncionales homobidentados y su uso en conjugados inmunologicamente activos. | |
IT8622630A0 (it) | Anticorpi monoclonali crossreattivi e cross-protettivi contro sierotipi di p. aeruginosa. | |
FI950062A (fi) | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten | |
FR2522967B1 (fr) | Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant | |
AU549495B2 (en) | Immunoglobulin-vindesine conjugates | |
KR890011603A (ko) | 항암 결합체 | |
DE69323713T2 (de) | Neue verbindungen und konjugate | |
JPS55136235A (en) | Antitumor protein complex and its preparation | |
NZ221065A (en) | Conjugates of antibodies and toxins with sulphur-containing linking groups | |
YU46858B (sh) | Postupak za dobijanje imunoglobulinskih konjugata | |
NO168746C (no) | Antistoff som er istand til aa binde histamin | |
KR890701130A (ko) | 안지오제닌(Angiogenin)에 대한 항체 : 면역제 | |
FI891816A0 (fi) | Monoklonal antikropp mot pseudomonas aeruginosa, dess framstaellning och anvaendning. | |
AU666707B2 (en) | Monoclonal anti-ganglioside antibody, its preparation and use as a tumortherapeutic agent | |
ES458411A1 (es) | Un metodo y un aparato inmunoquimico de separacion de frac- ciones libres de las combinadas en un proceso de inmunoana- lisis. | |
AU6596390A (en) | Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes | |
ATE136469T1 (de) | Neue verwendung eines monoklonalen antikörpers | |
CA2081879A1 (en) | Monoclonal antibodies to polyacrylate polymers |